INTRODUCTION
An accurate and timely evaluation of tumor response to treatment is critical to optimize cancer patient management. Dynamic contrast enhanced MRI (DCE-MRI) derives physiologically meaningful tumor vasculature parameters and are valuable to asses the efficacy of anti-cancer therapy.
Macromolecular contrast agents are better than small molecular contras agent in assessing the efficacy of anti-cancer therapy but are hindered by their high toxic Gd (III) tissues retention due to their prolonged blood circulation. Biodegradable macromolecular contrast agents (BMCA) alleviate this toxicity problem by in vivo degradation (accelerated excretion and minimum Gd (III) deposition). A BMCA, (Gd-DTPA)-cystamine copolymers (GDCC at 40 KDa, the renal filtration cutoff size), was used to assess the efficacy of indocyanine green enhanced photothermal therapy (DyeLA). , and permeability surface area product (PS).
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RESULTS and CONCLUSIONS
DyeLA treated tumors were significantly smaller than those untreated (1.1 ± 0.2 vs. 3.1 ± 1.2, normalized size) 12 days after treatment. Values of f PV and PS significantly dropped 4 hr after treatment and returned to close to normal values 7 days later (Fig. 1 ). Parameter mappings demonstrate the inhomogeneous tumor response to treatment when enhanced by GDCC and Gd-(DTPA-BMA) (Fig. 2) . The values estimated by Gd-(DTPA-BMA) are unrealistic too high due to its quick perfusion into extracellular and extravascular space. Therefore response assessed by DCE-MRI using GDCC is promising in timely and accurately evaluation of anti-cancer treatment. 
